Xiong, Liangwen

Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,300

Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy

Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., et al. (2018) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 244

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., et al. (2020) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 133

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 111